Clinical Trial: Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

This study is currently recruiting patients.

Sponsors and Collaborators: Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)


RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining imatinib mesylate with radiation therapy may kill more tumor cells.

PURPOSE: Phase I/II trial to compare the effectiveness of imatinib mesylate with or without radiation therapy in treating young patients who have newly diagnosed or recurrent glioma.

Condition Treatment or Intervention Phase
childhood central nervous system germ cell tumor
high-grade childhood cerebral astrocytoma
untreated childhood brain stem glioma
recurrent childhood brain stem glioma
recurrent childhood cerebral astrocytoma
 Drug: imatinib mesylate
 Procedure: adjuvant therapy
 Procedure: enzyme inhibitor therapy
 Procedure: protein tyrosine kinase inhibitor therapy
 Procedure: radiation therapy
Phase I
Phase II

MedlinePlus related topics:  Brain Cancer;   Cancer;   Cancer Alternative Therapy

Study Type: Interventional
Study Design: Treatment

Official Title: Phase I/II Study of Imatinib Mesylate With or Without Radiotherapy in Children With Newly Diagnosed Poor Prognosis Brainstem Glioma or Recurrent High-Grade Intracranial Glioma (Phase I, strata I and IIA closed to accrual as of 5/10/04.)

Further Study Details: 



  • Determine the therapeutic activity of this regimen in these patients. (Phase II)
  • Determine the pharmacokinetics of these regimens in these patients. (Phase I) (Phase I, strata I and IIA closed to accrual as of 5/10/04.)
  • Compare the effects of EIACD use in these patients when treated with this drug. (Phase I) (Phase I, strata I and IIA closed to accrual as of 5/10/04.)
  • Determine the progression-free survival and overall survival of patients treated with this drug. (Phase II)

OUTLINE: This is a phase I dose-escalation, multicenter study followed by a phase II. Patients are stratified according to tumor type (newly diagnosed intrinsic brainstem glioma vs recurrent/refractory intracranial high-grade glioma). Patients in stratum II (phase I only) are further stratified according to concurrent use of enzyme-inducing anticonvulsant drugs (EIACDs) (yes vs no). Patients are assigned to one of two strata in the phase I study.

  • Stratum I (newly diagnosed brainstem glioma): Patients undergo radiotherapy once daily five days a week for 6 weeks. Beginning 2-3 weeks after completion of radiotherapy, patients without evidence of intratumoral bleed receive oral imatinib mesylate twice daily. Imatinib mesylate treatment repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 5/10/04.)
  • Stratum II A (recurrent or refractory high-grade intracranial gliomas/no concurrent EIACs): Patients receive imatinib mesylate as in stratum I. (Closed to accrual as of 5/10/04).
  • Stratum II B (recurrent or refractory high-grade intracranial gliomas and concurrent EIACs): Patients receive imatinib mesylate as in stratum I. Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 5 of 6 patients experience no dose-limiting toxicity.
  • (Open to accrual as of 5/10/04.)
  • Stratum I only: Patients undergo radiotherapy as in phase I. Patients receive imatinib mesylate at the MTD established in phase I. Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 140 patients will be accrued for this study within 2 years.


Ages Eligible for Study:  3 Years   -   21 Years,  Genders Eligible for Study:  Both




  • 3 to 21

Performance status:

  • Karnofsky 50-100% OR
  • Lansky 50-100%

Life expectancy:

  • Not specified


  • Absolute neutrophil count greater than 1,000/mm^3
  • Platelet count greater than 100,000/mm^3 (transfusion independent)
  • Hemoglobin greater than 8 g/dL (transfusion allowed)


  • Bilirubin no greater than 1.5 times normal for age
  • SGPT less than 3 times normal for age
  • Albumin at least 2 g/dL
  • No significant hepatic disease


  • Creatinine less than 1.5 times normal for age OR
  • Glomerular filtration rate greater than 70 mL/min
  • No significant renal disease


  • No significant cardiac disease
  • No deep venous or arterial thrombosis within the past 6 weeks



  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for 6 months after study participation
  • No uncontrolled infection
  • No significant gastrointestinal disease
  • No significant psychiatric disease
  • Neurological deficits allowed if stable for at least 1 week prior to study (stratum II)



  • No prior chemotherapy (stratum I)
  • At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered (stratum II)

Endocrine therapy:

  • Prior routine corticosteroids allowed
  • Concurrent corticosteroids allowed if on stable or decreasing dose for at least 1 week prior to study



  • See Disease Characteristics


  • No prior imatinib mesylate (stratum II)
  • At least 2 weeks since beginning or discontinuing medications affecting cytochrome P450 3A4, 5, and 7 isoenzyme metabolism
  • No other concurrent anticancer drug
  • No other concurrent experimental drug
  • No concurrent warfarin
  • No concurrent enzyme-inducing anticonvulsant drugs (stratum I)

Location and Contact Information

      UCSF Comprehensive Cancer Center, San Francisco,  California,  94143,  United States; Recruiting
Michael Del Prados, MD  415-353-2966 

District of Columbia
      Children's National Medical Center, Washington,  District of Columbia,  20010-2970,  United States; Recruiting
Roger J. Packer, MD  202-884-2120 

      Children's Memorial Hospital - Chicago, Chicago,  Illinois,  60614,  United States; Recruiting
Stewart Goldman, MD  773-880-4585 

      Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda,  Maryland,  20892-1182,  United States; Recruiting
Patient Recruitment  888-NCI-1937 

      Children's Hospital Boston, Boston,  Massachusetts,  02115,  United States; Recruiting
Tina Young Poussaint, MD  617-355-6450 

      Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston,  Massachusetts,  02115,  United States; Recruiting
Mark William Kieran, MD  617-632-4907 

North Carolina
      Duke Comprehensive Cancer Center, Durham,  North Carolina,  27710,  United States; Recruiting
Henry S. Friedman, MD  919-684-5301 

      Children's Hospital of Philadelphia, Philadelphia,  Pennsylvania,  19104-4318,  United States; Recruiting
Peter C. Phillips, MD  215-590-2107 

      Children's Hospital of Pittsburgh, Pittsburgh,  Pennsylvania,  15213,  United States; Recruiting
Ian F. Pollack, MD  412-692-5881 

      St. Jude Children's Research Hospital, Memphis,  Tennessee,  38105-2794,  United States; Recruiting
James Boyett, PhD  901-495-3370 

      Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston,  Texas,  77030-2399,  United States; Recruiting
Susan M. Blaney, MD  832-822-1482 

      Children's Hospital and Regional Medical Center - Seattle, Seattle,  Washington,  98105,  United States; Recruiting
J. Russell Geyer, MD  206-987-6664 

Study chairs or principal investigators

Ian F. Pollack, MD,  Study Chair,  Children's Hospital of Pittsburgh   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000068761; PBTC-006; NCT00021229
Record last reviewed:  May 2004
Last Updated:  April 4, 2005
Record first received:  July 11, 2001 Identifier:  NCT00021229
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005